S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:PHAT

Phathom Pharmaceuticals (PHAT) Stock Price, News & Analysis

$10.62
-0.43 (-3.89%)
(As of 03/28/2024 ET)
Today's Range
$10.42
$11.22
50-Day Range
$6.21
$11.05
52-Week Range
$6.07
$17.02
Volume
886,406 shs
Average Volume
852,987 shs
Market Capitalization
$621.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.33

Phathom Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
100.9% Upside
$21.33 Price Target
Short Interest
Bearish
40.11% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.39mentions of Phathom Pharmaceuticals in the last 14 days
Based on 14 Articles This Week
Insider Trading
Selling Shares
$30.20 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.22) to ($3.24) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.82 out of 5 stars

Medical Sector

686th out of 938 stocks

Pharmaceutical Preparations Industry

306th out of 417 stocks

PHAT stock logo

About Phathom Pharmaceuticals Stock (NASDAQ:PHAT)

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

PHAT Stock Price History

PHAT Stock News Headlines

SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
SIGA Names Larry Miller General Counsel
Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
PHAT Apr 2024 10.000 call
Q4 2023 Phathom Pharmaceuticals Inc Earnings Call
Preview: Phathom Pharmaceuticals's Earnings
See More Headlines
Receive PHAT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Phathom Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/07/2024
Today
3/28/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PHAT
Fax
N/A
Employees
452
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$21.33
High Stock Price Target
$28.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+100.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-201,590,000.00
Pretax Margin
-29,558.95%

Debt

Sales & Book Value

Annual Sales
$680,000.00
Book Value
($1.27) per share

Miscellaneous

Free Float
42,630,000
Market Cap
$621.06 million
Optionable
Optionable
Beta
0.63
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

PHAT Stock Analysis - Frequently Asked Questions

Should I buy or sell Phathom Pharmaceuticals stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Phathom Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PHAT shares.
View PHAT analyst ratings
or view top-rated stocks.

What is Phathom Pharmaceuticals' stock price target for 2024?

4 brokerages have issued 12 month price objectives for Phathom Pharmaceuticals' shares. Their PHAT share price targets range from $10.00 to $28.00. On average, they predict the company's share price to reach $21.33 in the next year. This suggests a possible upside of 100.9% from the stock's current price.
View analysts price targets for PHAT
or view top-rated stocks among Wall Street analysts.

How have PHAT shares performed in 2024?

Phathom Pharmaceuticals' stock was trading at $9.13 at the start of the year. Since then, PHAT shares have increased by 16.3% and is now trading at $10.62.
View the best growth stocks for 2024 here
.

When is Phathom Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our PHAT earnings forecast
.

How were Phathom Pharmaceuticals' earnings last quarter?

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) released its quarterly earnings results on Thursday, March, 7th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.92) by $0.12. The firm had revenue of $0.68 million for the quarter, compared to the consensus estimate of $0.93 million. During the same period last year, the firm earned ($1.33) EPS.

What ETFs hold Phathom Pharmaceuticals' stock?

ETFs with the largest weight of Phathom Pharmaceuticals (NASDAQ:PHAT) stock in their portfolio include Simplify Propel Opportunities ETF (SURI).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

What other stocks do shareholders of Phathom Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Phathom Pharmaceuticals investors own include Clovis Oncology (CLVS), AbbVie (ABBV), Algonquin Power & Utilities (AQN), BCE (BCE), Cinemark (CNK), CenterPoint Energy (CNP), Canadian Natural Resources (CNQ), Brinker International (EAT) and Consolidated Edison (ED).

When did Phathom Pharmaceuticals IPO?

Phathom Pharmaceuticals (PHAT) raised $150 million in an IPO on Friday, October 25th 2019. The company issued 7,900,000 shares at a price of $18.00-$20.00 per share. Goldman Sachs, Jefferies and Evercore ISI served as the underwriters for the IPO and Needham & Company was co-manager.

Who are Phathom Pharmaceuticals' major shareholders?

Phathom Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.42%), Vanguard Group Inc. (3.35%), Avidity Partners Management LP (3.01%), Gilder Gagnon Howe & Co. LLC (2.54%), Decheng Capital LLC (1.48%) and Catalys Pacific LLC (1.26%). Insiders that own company stock include Asit Parikh, Azmi Nabulsi, David A Socks, Molly Henderson, Nathan Olmstead, Peter Bauer, Pharmaceutical Co Ltd Takeda and Terrie Curran.
View institutional ownership trends
.

How do I buy shares of Phathom Pharmaceuticals?

Shares of PHAT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PHAT) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners